Immunotherapy Explained Part 2 – In Relation To Affimed. In part 3 here we explain and expand in the science of Immunotherapy and explain in part how $AFMD is differentiated, explain the $MRK Keytruda/AFM 13 trial plus a lot more.…
Biotech and StockMarket Podcast May 31 2016… $IONS $RLYP Gold, Oil + Macros $IONs discussed here on why we took call options. Danny explains the situation there and why it’s not as bad as the market is thinking. We also…
Once again, in the September Federal Reserve (FED) policy meeting, the FED did not raise the fed fund rate, leaving it at 0% to 0.25%. The stock market has had a huge run since the lows of 2009. At their…
In small cap developmental biotech, we see a lot of creative financing, and when we understand how it works, we can profit from it. These types of biotech charts normally trade in a consistent ‘channel pattern.’ and when we spot…
Explanation on Current Market Situation Jan.29, 2014. $SPY reviewed later on in video. Mis-speak, I said “76 Million jobs” I later correct that to the proper “76 thousand jobs” I speak about potential head and shoulders in the charts, as…
Today at stockmatusow, we focus on a Bio-Pharmaceutical company with several near-term catalysts and give our thesis why we believe the company makes for a good long term speculative investment. Synergy Pharmaceuticals (SGYP) focuses on the development of drugs to…
Disclosure: I bought 25k shares of $PGNX @ $5.45 Biorunup’s Mark sold to go on vacation. Sheff remains bullish. we do as well. This is a pure catalyst trade which I talk about in my latest video. If Adcom for…
Merger and acquisition rumors are heard on a daily basis throughout the market. Some have merit and turn out to be true, while others turn out to be false and without merit. Today, I will cover some companies that I…
n a bit more deliberate than Jazz, but is coming along nicely. Antares started its royalty deals with a gel based platform, one being a royalty deal with Actavis, Inc. (NYSE: ACT) (formely Watson Pharma) for topical oxybutynin gel. Oxybutynin…
In my last article concerning Solta Medical Devices (SLTM), I remarked several times how I feel the company has good assets and the potential to grab significant market share in various segments. However, I do feel the company and its…
